ClinicalTrials.gg
CompletedNCT05254002CONFIDENCEUpdated Jul 13, 2026Results posted

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

A Phase 2 interventional study of Finerenone (BAY94-8862 ) 10 mg and Empagliflozin in Type 2 Diabetes Mellitus and Chronic Kidney Disease, sponsored by Bayer. Completed at 173 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,664
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing finerenone in Diabetes Mellitus, Type 2 — 5 open to participants now, 6 under way, none of them phase 3. finerenone · Diabetes Mellitus, Type 2.

Enrollment
3rd of 13
1,664 · median 100
Started
2022
the only one that year
Phase 2
3 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
5 of 13
Bayer

Among the 13 studies testing finerenone in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is the only one that started in 2022, is one of 3 in phase 2, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 13 studies testing finerenone in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing finerenone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.

Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine.

In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the participants' kidney function compared to either treatment alone. For this, the level of protein in the urine will be measured. The investigators also want to know how safe the combination is compared to either treatment alone.

Depending on the treatment group, the participants will either take the combination of finerenone and empagliflozin, or finerenone together with a placebo, or empagliflozin together with a placebo, once a day as tablets by mouth. A placebo looks like a treatment but does not have any medicine in it. Importantly, the participants will also continue to take their other current medicine for CKD and T2D.

The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, participants will visit the study site 7 times.

The study team will:

  • collect blood and urine samples
  • check the participants' vital signs
  • do a physical examination including height and weight
  • check the participants' heart health by using an electrocardiogram (ECG)
  • monitor the participants' blood pressure
  • ask the participants questions about how they are feeling and what adverse events they may be having An adverse event is any problem that happens during the trial. Doctors keep track of all events that happen in trials, even if they do not think the events might be related to the study treatments.
03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant with a clinical diagnosis of chronic kidney disease (CKD) and the following:

    • In Part A: 40-90 ml/min/1.73m\^2 (with no more than 20% having an eGFR >75 ml/min/1.73m\^2) using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula at screening visit and at least one historical value of eGFR \<60 mL/min/1.73 m\^2 within 3 months or have a registered diagnosis of CKD.
    • In Part B: eGFR 30-90 ml/min/1.73m\^2 (with no more than 20% having an eGFR >75 ml/min/1.73m\^2) using CKD-EPI formula at screening visit and at least one historical value of eGFR \<60 mL/min/1.73 m\^2 within 3 months or have a registered diagnostic of CKD.
    • 100 ≤UACR \<5000 mg/g at screening visit (mean value from 3 morning void samples) and documentation of albuminuria/proteinuria (quantitative or semi-quantitative measurement) in the participant's medical records at least 3 months prior to screening
  • Participant with type 2 diabetes (T2D) as defined by the American Diabetes Association (ADA 2021), with (HbA1c) at screening \<11%.
  • Participant treated with the clinically maximum tolerated dose, as per investigator judgment, of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), but not both, for more than 1 month at screening visit.

Exclusion criteria

Exclusion Criteria:

  • Participants with type 1 diabetes (T1D).
  • Participant with hepatic insufficiency classified as C.
  • Participant with blood pressure at Day 1 visit (Visit 2) higher than 160 systolic blood pressure (SBP) or 100 diastolic blood pressure (DBP) or SBP lower than 90 mmHg.
  • Participant currently treated with a sodium/glucose cotransporter-2 inhibitor (SGLT2i) or SGLT-1/2i or who received a SGLT2i or SGLT-1/2i which cannot be discontinued at least 8 weeks prior to the screening visit and during study intervention treatment.
  • Participant treated with another mineralocorticoid receptor antagonist (MRA) (e.g., eplerenone, esaxerenone, spironolactone, canrenone), a renin inhibitor, potassium supplements, a potassium sparing diuretic (e.g., amiloride, triamterene), a potassium binder agent, or angiotensin receptor-neprilysin inhibitor (ARNI) which cannot be discontinued at least 8 weeks prior to the screening visit and during study intervention treatment.
  • Participants currently treated or who were treated with Finerenone (Kerendia©) within 8 weeks prior to the screening visit.
  • Participant with serum/plasma potassium (K+) above 4.8 mmol/L at screening visit (central laboratory value).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,664 participants (actual)

Study arms

  • Experimental
    Finerenone and Empagliflozin

    Participants will take Finerenone (10 or 20 mg once daily \[OD\]) and Empagliflozin (10 mg OD) for up to 180 days.

    Drug: Finerenone (BAY94-8862 ) 10 mg · Drug: Empagliflozin · Drug: Finerenone (BAY94-8862 ) 20 mg

  • Experimental
    Finerenone and Empagliflozin placebo

    Participants will take Finerenone (10 or 20 mg OD) and matching placebo to Empagliflozin (OD) for up to 180 days.

    Drug: Finerenone (BAY94-8862 ) 10 mg · Drug: Empagliflozin Placebo · Drug: Finerenone (BAY94-8862 ) 20 mg

  • Experimental
    Empagliflozin and Finerenone placebo

    Participants will take Empagliflozin (10 mg OD) and matching placebo to Finerenone (OD). for up to 180 days.

    Drug: Empagliflozin · Drug: Finerenone Placebo

Interventions

  • oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2

  • oral administration, once daily

  • DrugEmpagliflozin Placebo

    Matching placebo to empagliflozin oral administration, once daily

  • oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2

  • DrugFinerenone Placebo

    Matching Placebo to Finerenone oral administration once daily

06

What researchers measure

Primary outcomes

  1. Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Empagliflozin Alone

    Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline, estimated using a mixed model for repeated measures. The treatment effect is expressed as the ratio of LS means for the combination therapy group compared with empagliflozin alone. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a marker of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with chronic kidney disease and type 2 diabetes.

    Time frame: Baseline and Day 180

  2. Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Finerenone Alone

    Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline in the combination therapy group compared with finerenone alone, estimated using a mixed model for repeated measures. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a measurement of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.

    Time frame: Baseline and Day 180

Secondary outcomes

  1. Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 210 Relative to Day 180

    Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 210 (30 days after stopping the treatment) relative to Day 180, estimated using a mixed model for repeated measures. A ratio above 1 indicates an increase in UACR at Day 210 compared with Day 180. UACR is a measurement of albuminuria, a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.

    Time frame: Up to 210 days

  2. Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at 30 Days After End of Treatment Relative to Baseline

    Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) relative to baseline, estimated using a mixed model for repeated measures. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a marker of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.

    Time frame: Baseline to Day 210 (30 days after End of Treatment)

  3. Number of Participants by Relative Change in UACR Category at Day 180 (>30%, >40%, >50%)

    This outcome summarizes the number of participants whose relative change from baseline in urine albumin-to-creatinine ratio (UACR) at Day 180 met prespecified category thresholds (\>30%, \>40%, or \>50%). Relative change was assessed based on baseline and post-baseline UACR measurements. Percentages were calculated using as denominator the number of participants with both a baseline and at least one post-baseline UACR assessment within the specified timeframe. Participants were classified independently within each category.

    Time frame: At Day 180

  4. Change From Baseline in eGFR at 30 Days

    Change from baseline to Day 30 in estimated glomerular filtration rate (eGFR) was evaluated for each treatment group. Change was calculated as the value at Day 30 minus the baseline value. Negative values indicate a decrease from baseline and positive values indicate an increase from baseline.

    Time frame: At Day 30

  5. Number of Participants With an eGFR Decline Greater Than 30% at 30 Days From Baseline

    Time frame: Up to 30 days

  6. Change in eGFR at 180 Days and 210 Days From Day 30

    Change in estimated glomerular filtration rate (eGFR) from Day 30 to Day 180 and Day 210 was evaluated for each treatment group. Change was calculated as the value at Day 180 or Day 210 minus the value at Day 30. Positive values indicate an increase from Day 30 and negative values indicate a decrease from Day 30.

    Time frame: At Day 180 and Day 210

  7. Number of Participants With AKI Events

    AKI is defined as any of the following: * An increase in serum creatinine by greater than or equal to 0.3 mg/dL within 48 hours; or * An increase in serum creatinine by greater than or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or * A urine volume less than 0.5 ml/kg/h for 6 hours Total number of AKI events Up to 180 days

    Time frame: Up to 180 days

  8. Total Number of AKI Events

    AKI is defined as any of the following: * An increase in serum creatinine by greater than or equal to 0.3 mg/dL within 48 hours; or * An increase in serum creatinine by greater than or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or * A urine volume less than 0.5 ml/kg/h for 6 hours Total number of AKI events Up to 180 days

    Time frame: Up to 180 days

  9. Number of Participants With Hyperkalemia Events (Moderate Hyperkalemia [5.5 <K+ ≤6.0 mmol/L], Severe Hyperkalemia [K+ >6.0 mmol/L])

    Moderate hyperkalemia was defined as K+ \>5.5 to ≤6.0 mmol/L and severe hyperkalemia was defined as K+ \>6.0 mmol/L).

    Time frame: Up to 180 days

  10. Change From Baseline in K+

    Serum potassium values (mmol/L) were assessed at baseline and scheduled post-baseline visits. Results are presented as observed mean potassium concentrations at each time point.

    Time frame: At baseline, day 14 and day 180

  11. Number of Participants With Symptomatic Hypotension Events

    Number of participants who experienced at least one symptomatic hypotension event during the study period

    Time frame: Up to 180 days

  12. Total Number of Symptomatic Hypotension Events

    Symptomatic hypotension events were assessed at all study visits and were documented as adverse events. The outcome represents the total number of symptomatic hypotension events reported during the study period.

    Time frame: Up to 180 days

  13. Number of Participants With Genital Mycotic Events

    The outcome represents the number of participants who experienced at least one genital mycotic event during the study period.

    Time frame: Up to 180 days

  14. Total Number of Genital Mycotic Events

    Occurrence of urinary tract infection events were assessed at all study visits and documented as AEs.

    Time frame: Up to 180 days

  15. Number of Participants With Urosepsis and Pyelonephritis Events

    Time frame: Up to 180 days

  16. Total Number of Urosepsis and Pyelonephritis Events

    Occurrence of urosepsis and pyelonephritis events were assessed at all study visits and documented as AEs.

    Time frame: Up to 180 days

  17. Number of Participants With Ketoacidosis Events

    Time frame: Up to 180 days

  18. Total Number of Ketoacidosis Events

    Occurrence of ketoacidosis events were assessed at all study visits and documented as AEs.

    Time frame: Up to 180 days

  19. Number of Participants With Necrotizing Fasciitis of the Perineum Events

    Time frame: Up to 180 days

  20. Number of Participants With Severe Hypoglycemia Events

    Severe hypoglycemia was defined as glucose level of \<3.0 mmol/L (\<54 mg/dL) is sufficiently low to indicate serious, clinically important hypoglycemia. In addition, severe hypoglycemia, as defined by the ADA denotes severe cognitive impairment requiring external assistance for recovery.

    Time frame: Up to 180 days

07

Results

Posted Jul 13, 2026
Limitations and caveats
The trial used a surrogate end point, and we did not follow the participants long enough to adequately measure differences among groups in cardiovascular outcomes or clinical kidney disease progression.

Participant flow

A total of 1664 participants were screened and signed the informed consent form for the study. 846 participants were screen failures and did not complete screening. The study was conducted at 163 centers in 14 countries/regions across Asia, Europe and North America from 23 Jun 2022 (First Patient First Visit) to 17 Mar 2025 (Last Patient Last Visit).

Participant flow — Overall Study
MilestoneFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Started273273272
Treated271270271
Included in full analysis set (fas)269264267
Included in safety analysis set (saf)268264266
Completed240232238
Not completed334134
Withdrew: Adverse event131110
Withdrew: Death102
Withdrew: Physician decision520
Withdrew: Withdrawal by subject51210
Withdrew: Lost to follow-up233
Withdrew: Randomized by mistake102
Withdrew: Other reasons141
Withdrew: Gcp violation365
Withdrew: Never took study drug231

Outcome measures

PrimaryLeast Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Empagliflozin Alone

Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline, estimated using a mixed model for repeated measures. The treatment effect is expressed as the ratio of LS means for the combination therapy group compared with empagliflozin alone. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a marker of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with chronic kidney disease and type 2 diabetes.

Time frame:
Baseline and Day 180
Reported as:
Least squares mean · ratio
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Empagliflozin Alone
ratioFinerenone and EmpagliflozinEmpagliflozin and Finerenone Placebo
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Empagliflozin Alone0.483 (0.435 to 0.537)0.708 (0.636 to 0.789)
PrimaryLeast Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Finerenone Alone

Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 180 relative to baseline in the combination therapy group compared with finerenone alone, estimated using a mixed model for repeated measures. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a measurement of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.

Time frame:
Baseline and Day 180
Reported as:
Least squares mean · Ratio
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Finerenone Alone
RatioFinerenone and EmpagliflozinFinerenone and Empagliflozin Placebo
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Finerenone Alone0.483 (0.435 to 0.537)0.683 (0.613 to 0.761)
SecondaryLeast Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 210 Relative to Day 180

Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) at Day 210 (30 days after stopping the treatment) relative to Day 180, estimated using a mixed model for repeated measures. A ratio above 1 indicates an increase in UACR at Day 210 compared with Day 180. UACR is a measurement of albuminuria, a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.

Time frame:
Up to 210 days
Reported as:
Least squares mean · ratio
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 210 Relative to Day 180
ratioFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 210 Relative to Day 1801.631 (1.493 to 1.782)1.448 (1.323 to 1.585)1.442 (1.318 to 1.577)
SecondaryLeast Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at 30 Days After End of Treatment Relative to Baseline

Least squares mean ratio of urinary albumin-to-creatinine ratio (UACR) relative to baseline, estimated using a mixed model for repeated measures. A ratio below 1 indicates a reduction in UACR relative to baseline. UACR is a marker of albuminuria and a predictor of long-term renal and cardiovascular outcomes in participants with type 2 diabetes.

Time frame:
Baseline to Day 210 (30 days after End of Treatment)
Reported as:
Least squares mean · ratio
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at 30 Days After End of Treatment Relative to Baseline
ratioFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at 30 Days After End of Treatment Relative to Baseline0.818 (0.734 to 0.911)0.853 (0.762 to 0.956)0.895 (0.801 to 1.000)
SecondaryNumber of Participants by Relative Change in UACR Category at Day 180 (>30%, >40%, >50%)

This outcome summarizes the number of participants whose relative change from baseline in urine albumin-to-creatinine ratio (UACR) at Day 180 met prespecified category thresholds (\>30%, \>40%, or \>50%). Relative change was assessed based on baseline and post-baseline UACR measurements. Percentages were calculated using as denominator the number of participants with both a baseline and at least one post-baseline UACR assessment within the specified timeframe. Participants were classified independently within each category.

Time frame:
At Day 180
Reported as:
Count of participants · Participants
Number of Participants by Relative Change in UACR Category at Day 180 (>30%, >40%, >50%)
ParticipantsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Participants with relative change from baseline in UACR >30% at Day 180168123123
Participants with relative change from baseline in UACR >40% at Day 180154104103
Participants with relative change from baseline in UACR >50% at Day 1801318476
SecondaryChange From Baseline in eGFR at 30 Days

Change from baseline to Day 30 in estimated glomerular filtration rate (eGFR) was evaluated for each treatment group. Change was calculated as the value at Day 30 minus the baseline value. Negative values indicate a decrease from baseline and positive values indicate an increase from baseline.

Time frame:
At Day 30
Reported as:
Least squares mean · mL/min/1.73 m^2
Change From Baseline in eGFR at 30 Days
mL/min/1.73 m^2Finerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Change From Baseline in eGFR at 30 Days-5.593 (-6.669 to -4.517)-2.036 (-3.131 to -0.941)-3.788 (-4.878 to -2.698)
SecondaryNumber of Participants With an eGFR Decline Greater Than 30% at 30 Days From Baseline
Time frame:
Up to 30 days
Reported as:
Count of participants · Participants
Number of Participants With an eGFR Decline Greater Than 30% at 30 Days From Baseline
ParticipantsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Number of Participants With an eGFR Decline Greater Than 30% at 30 Days From Baseline17103
SecondaryChange in eGFR at 180 Days and 210 Days From Day 30

Change in estimated glomerular filtration rate (eGFR) from Day 30 to Day 180 and Day 210 was evaluated for each treatment group. Change was calculated as the value at Day 180 or Day 210 minus the value at Day 30. Positive values indicate an increase from Day 30 and negative values indicate a decrease from Day 30.

Time frame:
At Day 180 and Day 210
Reported as:
Least squares mean · mL/min/1.73 m^2
Change in eGFR at 180 Days and 210 Days From Day 30
mL/min/1.73 m^2Finerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Day 1800.874 (-0.266 to 2.015)-0.285 (-1.487 to 0.917)1.255 (0.107 to 2.402)
Day 2105.120 (3.993 to 6.247)0.953 (-0.264 to 2.170)3.976 (2.826 to 5.126)
SecondaryNumber of Participants With AKI Events

AKI is defined as any of the following: * An increase in serum creatinine by greater than or equal to 0.3 mg/dL within 48 hours; or * An increase in serum creatinine by greater than or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or * A urine volume less than 0.5 ml/kg/h for 6 hours Total number of AKI events Up to 180 days

Time frame:
Up to 180 days
Reported as:
Count of participants · Participants
Number of Participants With AKI Events
ParticipantsFinerenone and EmpagliflozinFinerenone and Emagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Number of Participants With AKI Events530
SecondaryTotal Number of AKI Events

AKI is defined as any of the following: * An increase in serum creatinine by greater than or equal to 0.3 mg/dL within 48 hours; or * An increase in serum creatinine by greater than or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or * A urine volume less than 0.5 ml/kg/h for 6 hours Total number of AKI events Up to 180 days

Time frame:
Up to 180 days
Reported as:
Number · events
Total Number of AKI Events
eventsFinerenone and EmpagliflozinFinerenone and Emagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Total Number of AKI Events530
SecondaryNumber of Participants With Hyperkalemia Events (Moderate Hyperkalemia [5.5 <K+ ≤6.0 mmol/L], Severe Hyperkalemia [K+ >6.0 mmol/L])

Moderate hyperkalemia was defined as K+ \>5.5 to ≤6.0 mmol/L and severe hyperkalemia was defined as K+ \>6.0 mmol/L).

Time frame:
Up to 180 days
Reported as:
Count of participants · Participants
Number of Participants With Hyperkalemia Events (Moderate Hyperkalemia [5.5 <K+ ≤6.0 mmol/L], Severe Hyperkalemia [K+ >6.0 mmol/L])
ParticipantsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Moderate Hyperkalemia Events (K+ >5.5 mmol/L to ≤6.0 mmol/L)334020
Severe Hyperkalemia Events (K+ >6.0 mmol/L)12127
SecondaryChange From Baseline in K+

Serum potassium values (mmol/L) were assessed at baseline and scheduled post-baseline visits. Results are presented as observed mean potassium concentrations at each time point.

Time frame:
At baseline, day 14 and day 180
Reported as:
Mean · mmol/L
Change From Baseline in K+
mmol/LFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Baseline4.42 ± 0.394.51 ± 0.464.52 ± 0.41
Day 144.68 ± 0.484.70 ± 0.514.53 ± 0.41
Day 1804.67 ± 0.514.68 ± 0.544.55 ± 0.48
SecondaryNumber of Participants With Symptomatic Hypotension Events

Number of participants who experienced at least one symptomatic hypotension event during the study period

Time frame:
Up to 180 days
Reported as:
Count of participants · Participants
Number of Participants With Symptomatic Hypotension Events
ParticipantsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Number of Participants With Symptomatic Hypotension Events300
SecondaryTotal Number of Symptomatic Hypotension Events

Symptomatic hypotension events were assessed at all study visits and were documented as adverse events. The outcome represents the total number of symptomatic hypotension events reported during the study period.

Time frame:
Up to 180 days
Reported as:
Number · events
Total Number of Symptomatic Hypotension Events
eventsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Total Number of Symptomatic Hypotension Events300
SecondaryNumber of Participants With Genital Mycotic Events

The outcome represents the number of participants who experienced at least one genital mycotic event during the study period.

Time frame:
Up to 180 days
Reported as:
Count of participants · Participants
Number of Participants With Genital Mycotic Events
ParticipantsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Number of Participants With Genital Mycotic Events404
SecondaryTotal Number of Genital Mycotic Events

Occurrence of urinary tract infection events were assessed at all study visits and documented as AEs.

Time frame:
Up to 180 days
Reported as:
Number · events
Total Number of Genital Mycotic Events
eventsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Total Number of Genital Mycotic Events406
SecondaryNumber of Participants With Urosepsis and Pyelonephritis Events
Time frame:
Up to 180 days
Reported as:
Count of participants · Participants
Number of Participants With Urosepsis and Pyelonephritis Events
ParticipantsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Number of Participants With Urosepsis and Pyelonephritis Events101
SecondaryTotal Number of Urosepsis and Pyelonephritis Events

Occurrence of urosepsis and pyelonephritis events were assessed at all study visits and documented as AEs.

Time frame:
Up to 180 days
Reported as:
Number · events
Total Number of Urosepsis and Pyelonephritis Events
eventsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Total Number of Urosepsis and Pyelonephritis Events201
SecondaryNumber of Participants With Ketoacidosis Events
Time frame:
Up to 180 days
Reported as:
Count of participants · Participants
Number of Participants With Ketoacidosis Events
ParticipantsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Number of Participants With Ketoacidosis Events000
SecondaryTotal Number of Ketoacidosis Events

Occurrence of ketoacidosis events were assessed at all study visits and documented as AEs.

Time frame:
Up to 180 days
Reported as:
Number · events
Total Number of Ketoacidosis Events
eventsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Total Number of Ketoacidosis Events000
SecondaryNumber of Participants With Necrotizing Fasciitis of the Perineum Events
Time frame:
Up to 180 days
Reported as:
Count of participants · Participants
Number of Participants With Necrotizing Fasciitis of the Perineum Events
ParticipantsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Number of Participants With Necrotizing Fasciitis of the Perineum Events000
SecondaryNumber of Participants With Severe Hypoglycemia Events

Severe hypoglycemia was defined as glucose level of \<3.0 mmol/L (\<54 mg/dL) is sufficiently low to indicate serious, clinically important hypoglycemia. In addition, severe hypoglycemia, as defined by the ADA denotes severe cognitive impairment requiring external assistance for recovery.

Time frame:
Up to 180 days
Reported as:
Count of participants · Participants
Number of Participants With Severe Hypoglycemia Events
ParticipantsFinerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone Placebo
Number of Participants With Severe Hypoglycemia Events000

Adverse events

Collected over All-cause mortality was assessed from the randomization through the end of follow-up (up to 210 days). Serious and other adverse events were assessed from the first dose through the end of follow-up, including the treatment period (approximately 180 days) and the post-treatment follow-up period up to 30 days after the last dose (Day 210).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Finerenone + Empagliflozin Group3/268 (1.1%)19/268 (7.1%)141/268 (52.6%)
Finerenone Group0/264 (0%)16/264 (6.1%)136/264 (51.5%)
Empagliflozin Group3/266 (1.1%)17/266 (6.4%)129/266 (48.5%)
Never Received Treatment0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventFinerenone + Empagliflozin GroupFinerenone GroupEmpagliflozin GroupNever Received Treatment
CellulitisInfections and infestations1/2683/2641/2660/2
Acute kidney injuryRenal and urinary disorders0/2682/2640/2660/2
PneumoniaInfections and infestations0/2681/2642/2660/2
Chest painGeneral disorders and administration site conditions2/2681/2640/2660/2
Retinal artery occlusionEye disorders0/2681/2640/2660/2
Appendicitis perforatedInfections and infestations0/2681/2640/2660/2
Pneumonia aspirationInfections and infestations0/2681/2640/2660/2
Urinary tract infectionInfections and infestations1/2681/2640/2660/2
Campylobacter colitisInfections and infestations0/2681/2640/2660/2
COVID-19Infections and infestations0/2681/2640/2660/2
Most frequent other events
Showing 10 of 323
Most frequent other events
EventFinerenone + Empagliflozin GroupFinerenone GroupEmpagliflozin GroupNever Received Treatment
HyperkalaemiaMetabolism and nutrition disorders25/26827/26410/2660/2
Glomerular filtration rate decreasedInvestigations17/26811/26410/2660/2
NasopharyngitisInfections and infestations3/2687/26411/2660/2
DiarrhoeaGastrointestinal disorders9/2689/2646/2660/2
DizzinessNervous system disorders9/2688/2642/2660/2
Urinary tract infectionInfections and infestations6/2682/2648/2660/2
FatigueGeneral disorders and administration site conditions3/2687/2642/2660/2
ArthralgiaMusculoskeletal and connective tissue disorders1/2687/2642/2660/2
HypertensionVascular disorders1/2683/2647/2660/2
Blood creatinine increasedInvestigations7/2681/2640/2660/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Finerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone PlaceboTotal
Mean67.7 ± 10.065.5 ± 10.766.2 ± 10.166.5 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Finerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone PlaceboTotal
Female676170198
Male202203197602
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Finerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone PlaceboTotal
Hispanic or Latino28262983
Not Hispanic or Latino239235238712
Unknown or Not Reported2305
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Finerenone and EmpagliflozinFinerenone and Empagliflozin PlaceboEmpagliflozin and Finerenone PlaceboTotal
American Indian or Alaska Native1214
Asian114132125371
Native Hawaiian or Other Pacific Islander1001
Black or African American22212467
White130105116351
More than one race0000
Unknown or Not Reported1416
08

Study locations

173 sites
  • Southwest Kidney Institute, PLC - Suprise
    Surprise, Arizona 85374, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • Dignity Health Northridge Hospital Medical Center - Nephrology
    Northridge, California 91325, United States
  • Olive View - UCLA Medical Center
    Sylmar, California 91342-1437, United States
  • Touro University California - Metabolic Research Center
    Vallejo, California 94592, United States
  • Florida Kidney Physicians - Delray Beach Nephrology
    Delray Beach, Florida 33445, United States
  • West Orange Endocrinology & Clinical Research
    Ocoee, Florida 34761, United States
  • Innovative Research Institute
    Port Charlotte, Florida 33952, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • Grady Memorial Hospital - Endocrinology
    Atlanta, Georgia 30303, United States
  • Southeast Kidney Associates - East Point
    East Point, Georgia 30344, United States
  • Velocity Clinical Research - Savannah
    Savannah, Georgia 31406, United States
  • Nola Care Clinical Research
    Metairie, Louisiana 70006, United States
  • Omega Clinical Research - Metairie
    Metairie, Louisiana 70006, United States
  • South Shore Nephrology
    Plymouth, Massachusetts 02360, United States
  • Lake Michigan Nephrology
    Saint Joseph, Michigan 49085, United States
  • Oakland Medical Research
    Troy, Michigan 48085, United States
  • Clinical Research Consultants, a JCCT Company
    Kansas City, Missouri 64111, United States
  • Kansas City VA Medical Center - Endocrinology
    Kansas City, Missouri 64128, United States
  • Center for Advanced Medicine - Diabetes Center
    St Louis, Missouri 63110, United States
  • St. Louis Heart and Vascular, PC - Christian Hospital Office
    St Louis, Missouri 63136, United States
  • Somnos Clinical Research
    Lincoln, Nebraska 68510, United States
  • Healor Primary Care / CCT Research
    Las Vegas, Nevada 89102, United States
  • CCT Research - Santa Rosa Medical Centers of Nevada
    Las Vegas, Nevada 89119, United States
  • Circuit Clinical/Crystal Run
    Middletown, New York 10941, United States
  • Randolph Health Internal Medicine in Asheboro
    Asheboro, North Carolina 27203, United States
  • UNC Hospitals Outpatient Center at Eastowne - Nephrology
    Chapel Hill, North Carolina 27514, United States
  • Eastern Nephrology Associates - Greenville West
    Greenville, North Carolina 27834, United States
  • Blue Sky, MD/ Lamond Family Medicine
    Hendersonville, North Carolina 28792, United States
  • Eastern Nephrology Associates - Kinston
    Kinston, North Carolina 28504, United States
  • Velocity Clinical Research - Blue Ash
    Cincinnati, Ohio 45242, United States
  • Dunes Clinical Research LLC
    Dakota Dunes, South Dakota 57049, United States
  • DarSalud Care / LifeDOC Research
    Memphis, Tennessee 38119, United States
  • The University of Tennessee Health Science Center - Medical Center Clinic - Nephrology
    Memphis, Tennessee 38163, United States
  • Office of Osvaldo A. Brusco, MD
    Corpus Christi, Texas 78414, United States
  • Thyroid, Endocrinology, and Diabetes - Dallas
    Dallas, Texas 75208, United States
  • DaVita Clinical Research- El Paso
    El Paso, Texas 79925, United States
  • Global Kidney Center
    Houston, Texas 77008, United States
  • Victorium Clinical Research
    Houston, Texas 77024-2593, United States
  • North Texas Kidney Disease Associates Lewisville
    Lewisville, Texas 75057, United States
  • Biopharma Informatic - McAllen, TX
    McAllen, Texas 78503, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212, United States
  • UT Health San Antonio - Medical Arts & Research Center - Endocrinology
    San Antonio, Texas 78229, United States
  • Olympus Family Medicine
    Salt Lake City, Utah 84117, United States
  • Salem VA Medical Center - Endocrinology
    Salem, Virginia 24153, United States
  • MultiCare Rockwood Clinic Diabetes & Endocrinology Center
    Spokane, Washington 99202, United States
  • CHU de Charleroi Hôpital civil
    Lodelinsart, Hainaut 6042, Belgium
  • Onze-Lieve-Vrouwziekenhuis (OLVZ) - Campus Aalst
    Aalst, Oost-vlaanderen 9300, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • Jan Yperman Ziekenhuis
    Ieper, 8900, Belgium
  • AZ Groeninge Campus Kennedylaan
    Kortrijk, 8500, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • Hamilton Medical Research Group
    Hamilton, Ontario L8M 1K7, Canada
  • William Osler Health centre, Sakuara Medical
    Mississauga, Ontario L5H4K9, Canada
  • Bluewater Clinical Research Group
    Sarnia, Ontario N7T 4X3, Canada
  • Sameh Fikry Professional Corporation
    Waterloo, Ontario N2J 1C4, Canada
  • Clinical Research Solutions, Inc.
    Waterloo, Ontario N2T 0C1, Canada
  • GCP Research | Montreal
    Montreal, Quebec H1M 1B1, Canada
  • Centre Hospitalier de l'Universite de Montreal (CHUM) | Cardiology
    Montreal, Quebec H2X 0A9, Canada
  • LMC Clinical Research Inc. Montreal
    Saint-Laurent, Quebec H4T 1Z9, Canada
  • Bispebjerg Hospital - Hjerteafdeling
    Copenhagen, Capital Region 2400, Denmark
  • Steno Diabetes Center Copenhagen | Herlev - Clinical and Translational Research Department
    Herlev, Capital Region 2730, Denmark
  • Region Midtjylland | Regionshospitalet Godstrup - Nephrology Department
    Herning, Central Jutland 7400, Denmark
  • Hospital of South West Jutland | Department of Endocrinology Research
    Esbjerg, Region Syddanmark 6700, Denmark
  • Center Hospitalier Michallon - Grenoble
    La Tronche (Grenoble Area), Auvergne-Rhône-Alpes 38043, France
  • Hôpital Edouard Herriot - Lyon Cedex
    Lyon, Auvergne-Rhône-Alpes 69003, France
  • CHU Dijon - Hopital Francois Miterrand
    Dijon, Bourgogne-Franche-Comté 21000, France
  • Hopital Carémeau - Nîmes
    Nîmes, Occitanie 30029, France
  • Many Locations
    Many Locations, France
  • Hôpital Saint Joseph
    Paris, Île-de-France Region 75014, France
  • Diabetes Zentrum Wandsbek
    Hamburg, Free and Hanseatic City of Hamburg 22041, Germany
  • ClinPhenomics GmbH&Co. KG
    Frankfurt am Main, Hesse 60596, Germany
  • Diabetologische Schwerpunkt Praxis Dortmund
    Dortmund, North Rhine-Westphalia 44137, Germany
  • Zentrum für Diabetologie und Ernährungsmedizin
    Ludwigshafen am Rhein, Rhineland-Palatinate 67059, Germany
  • Cardiologicum Pirna / Dresden-Seidnitz
    Pirna, Saxony 1796, Germany
  • Charité Campus Benjamin Franklin (CBF)
    Berlin, State of Berlin 12203, Germany
  • Friedrich-Schiller-Uni. Jena
    Jena, Thuringia 7747, Germany
  • King George Hospital
    Visakhapatnam, Andhra Pradesh 530002, India
  • Mavani Dialysis & Kidney Center
    Ahmedabad, Gujarat 380052, India
  • Vedanta Kidney Care
    Vadodara, Gujarat 390007, India
  • K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre
    Belagavi, Karnataka 590010, India
  • Vinaya Hospital and Research Centre (A Unit of KIMS)
    Mangalore, Karnataka 575003, India
  • Manipal Hospital
    Mysore, Karnataka 570015, India
  • Government Medical College
    Kozhikode, Kerala 673008, India
  • Seth Gordhandas Sunderdas Medical College (GSMC) - King Edward Memorial (KEM) Hospital
    Mumbai, Maharashtra 400012, India
  • Asian Kidney Hospital and Medical Centre
    Nagpur, Maharashtra 440010, India
  • Grant Medical Foundation - Ruby Hall Clinic (RHC)
    Pune, Maharashtra 411001, India
  • All India Institute of Medical Sciences
    Bhubaneswar, National Capital Territory of Delhi 751019, India
  • Indraprastha Apollo Hospital
    New Delhi, National Capital Territory of Delhi 110076, India
  • Sawami Man Singh (SMS) Medical College & Attached Hospitals
    Jaipur, Rajasthan 302017, India
  • Eternal Heart Care Centre (EHCC) and Research Institute
    Jaipur, Rajasthan 302020, India
  • Government Kilpauk Medical College Hospital
    Chennai, Tamil Nadu 600010, India
  • Nizam's Institute of Medical Sciences (NIMS)
    Hyderabad, Telangana 500082, India
  • Krishna Institute Of Medical Science
    Secunderabad, Telangana 500003, India
  • Osmania General Hospital
    Telangana, Telangana 500012, India
  • G.S.V.M. Medical College
    Kanpur, Uttar Pradesh 208002, India
  • Institute of Post-Graduate Medical Education and Research
    Kolkata, West Bengal 700020, India
  • Dr. Bantwal's Clinic
    Bengaluru, 560076, India
  • Bangalore Medical College & Research Institute
    Bengaluru, India

Showing the first 100 of 173 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Agarwal R, Correa-Rotter R, Navaneethan SD, Heerspink HJL, Weir MR, McGill JB, Mottl AK, Nangaku M, Rosenstock J, Rossing P, Vaduganathan M, Scott C, Li L, Brinker M, Kovesdy CP, Green JB, Mann JFE. Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure. Hypertension. 2026 Jun 5. doi: 10.1161/HYPERTENSIONAHA.126.27036. Online ahead of print. PubMed 42244376 ↗
  • Agarwal R, Correa-Rotter R, Navaneethan SD, Fukami K, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Nangaku M, Rosenstock J, Rossing P, Vaduganathan M, Scott C, Li L, Aldworth C, Green JB, Weir MR. Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone. J Am Soc Nephrol. 2026 Mar 29. doi: 10.1681/ASN.0000001071. Online ahead of print. PubMed 41905767 ↗
  • Agarwal R, Green JB, Heerspink HJL, McGill JB, Mottl A, Nangaku M, Rosenstock J, Rossing P, Vaduganathan M, Solis-Herrera C, Scott C, Li L, Brinker M, Aldworth C, Mann JFE. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial. J Am Coll Cardiol. 2026 Feb 24;87(7):772-784. doi: 10.1016/j.jacc.2025.10.049. Epub 2025 Nov 7. PubMed 41493296 ↗
  • Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R; CONFIDENCE Trial Investigators. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2026 Apr 1;37(4):764-776. doi: 10.1681/ASN.0000000928. Epub 2025 Nov 6. PubMed 41196655 ↗
  • Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl A, Osonoi T, Pal A, Rossing P, Rosenstock J, Vaduganathan M, Li L, Li N, Scott C, Manjrekar P, Yamashita S, Nangaku M. Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE. Clin J Am Soc Nephrol. 2026 Jan 1;21(1):72-82. doi: 10.2215/CJN.0000000865. Epub 2025 Sep 18. PubMed 40965042 ↗
  • Vaduganathan M, Green JB, Heerspink HJL, Kim SG, Mann JFE, McGill JB, Mottl A, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Rohwedder K, Scott C, Agarwal R. Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial. Nephrol Dial Transplant. 2025 Dec 23;41(1):161-170. doi: 10.1093/ndt/gfaf160. PubMed 40886054 ↗
  • Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5. PubMed 40470996 ↗
  • Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE investigators. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics. Nephrol Dial Transplant. 2025 Aug 1;40(8):1559-1569. doi: 10.1093/ndt/gfaf022. PubMed 39916475 ↗
  • Rossing P. Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases. J Am Soc Nephrol. 2024 Oct 1;35(10):1438-1441. doi: 10.1681/ASN.0000000000000449. Epub 2024 Jul 5. No abstract available. PubMed 39078403 ↗
  • Zachariah T, Radhakrishnan J. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease. Clin J Am Soc Nephrol. 2024 Nov 1;19(11):1499-1512. doi: 10.2215/CJN.0000000000000540. Epub 2024 Jul 22. PubMed 39037799 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Mar 2025, 32 months.

Results were first posted in Jul 2026, 1 year 3 months after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 32 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2022
First posted
Feb 24, 2022
StartActual
Jun 23, 2022
Primary completionActual
Mar 14, 2025
CompletionActual
Mar 17, 2025
Results first posted
Jul 13, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05254002
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 24, 2022
Start date
Jun 23, 2022
Primary completion
Mar 14, 2025
Completion
Mar 17, 2025
Results posted
Jul 13, 2026
Last update
Jul 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Finerenone · Empagliflozin

Start the discussion